secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001600620-25-000083
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia announces positive Phase 1 results for aritinercept; robust Ig reductions support once-monthly dosing
--------------------------------------------------------------------------------

- Single doses of aritinercept (5-300 mg s.c.) well tolerated in 61 healthy subjects; no treatment-related Grade ≥3 AEs or SAEs.
- Mean immunoglobin reductions at Day 28: IgA up to 48%, IgM up to 55%, IgG up to 20%.
- Injection site reactions in 24% aritinercept vs 13% placebo; all Grade 1.
- Company plans to initiate clinical studies in at least two autoimmune diseases in H2 2025.
- Pharmacodynamic effects support once-monthly subcutaneous dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062025000083/0001600620-25-000083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062025000083/auph-20250630.htm
  HTML page:      https://secwatch.observer/filing/0001600620-25-000083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer